Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.6 USD | -10.03% | -21.21% | +161.96% |
Apr. 18 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
Mar. 06 | Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 23.49M | Capitalization | 104M |
---|---|---|---|---|---|
Net income 2024 * | -61M | Net income 2025 * | -54M | EV / Sales 2024 * | - |
Net cash position 2024 * | 86M | Net cash position 2025 * | 68M | EV / Sales 2025 * | 1.55 x |
P/E ratio 2024 * |
-2.32
x | P/E ratio 2025 * |
-2.43
x | Employees | 57 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.8% |
Latest transcript on Rezolute, Inc.
1 day | -10.03% | ||
1 week | -21.21% | ||
Current month | +1.96% | ||
1 month | +37.57% | ||
3 months | +132.14% | ||
6 months | +152.43% | ||
Current year | +161.96% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 66 | 10-07-25 | |
Nevan Elam
CEO | Chief Executive Officer | 56 | 10-07-25 |
Daron Evans
DFI | Director of Finance/CFO | 50 | Jan. 23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nevan Elam
CEO | Chief Executive Officer | 56 | 10-07-25 |
Young-Jin Kim
BRD | Director/Board Member | 67 | 19-02-09 |
Gil Labrucherie
BRD | Director/Board Member | 52 | 19-11-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 2.6 | -10.03% | 455,095 |
24-04-24 | 2.89 | +1.05% | 343,913 |
24-04-23 | 2.86 | -19.21% | 940,007 |
24-04-22 | 3.54 | +3.21% | 333,631 |
24-04-19 | 3.43 | +3.94% | 342,980 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+161.96% | 104M | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.70% | 22.02B | |
-17.84% | 20.9B | |
-10.07% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- RZLT Stock